Johnson & Johnson Partner Contineum Slides as Depression Drug Fails
Contineum Therapeutics, Inc. (NASDAQ: CTNM ) shares are trading lower on Tuesday as Phase 2 results from a key study disappoint. The pullback lines up with a risk-off tone in futures, but the company-specific clinical update appears to be the main driver. CTNM Stock Drops After Phase 2 MOONLIGHT-1 Results The company said its Phase 2 MOONLIGHT-1 trial did not meet its primary efficacy endpoint for JNJ-5120 / PIPE-307 in major depressive disorder. JNJ-5120/PIPE-307 is being developed by Johnson & Johnson (NYSE: JNJ ) under a global license and development agreement. Johnson & Johnson continues to evaluate the trial data, including data related to prespecified exploratory endpoints, and assess the totality and clinical relevance of the findings to inform next steps for JNJ-5120/PIPE-307. Read Also: Contineum Therapeutics Stock Edges Higher As PIPE-791 Pain Data Clears Safety Bar Trend Setup Versus News-Driven Volatility The bigger-picture backdrop is still constructive on paper—there’s a bullish 20-day-over-50-day alignment and a golden cross (50-day SMA over 200-day SMA) that dates back to September 2025—but the premarket drop risks turning that into a "trend vs. news" tug-of-war. W
Contineum Therapeutics, Inc. (NASDAQ: CTNM ) shares are trading lower on Tuesday as Phase 2 results from a key study disappoint. The pullback lines up with a risk-off tone in futures, but the company-specific clinical update appears to be the main driver. CTNM Stock Drops After Phase 2 MOONLIGHT-1 Results The company said its Phase 2 MOONLIGHT-1 trial did not meet its primary efficacy endpoint for JNJ-5120 / PIPE-307 in major depressive disorder.
JNJ-5120/PIPE-307 is being developed by Johnson & Johnson (NYSE: JNJ ) under a global license and development agreement. Johnson & Johnson continues to evaluate the trial data, including data related to prespecified exploratory endpoints, and assess the totality and clinical relevance of the findings to inform next steps for JNJ-5120/PIPE-307.
Read Also: Contineum Therapeutics Stock Edges Higher As PIPE-791 Pain Data Clears Safety Bar Trend Setup Versus News-Driven Volatility The bigger-picture backdrop is still constructive on paper—there’s a bullish 20-day-over-50-day alignment and a golden cross (50-day SMA over 200-day SMA) that dates back to September 2025—but the premarket drop risks turning that into a "trend vs. news" tug-of-war. 79 and a 52-week high set in September, traders will be watching whether this dip becomes another higher low or the start of a deeper reset. 61) — The stock has been showing stronger-than-average momentum on a multi-week basis, even with the current premarket dip.
The Verdict: Contineum Therapeutics’ Edge signal reveals a momentum-driven profile, with Momentum as the only scored pillar currently available. With today’s news-driven gap lower, traders will likely treat that momentum score as "under review" until the stock proves it can reclaim key moving averages on follow-through volume. 40 at the time of publication on Tuesday, according to Pro data. Read Also: Sam Altman’s AI Nightmare Splits ETF Trade: Build Vs.
Control Photo: Shutterstock